Small molecule-chemotherapy combinations: ibrutinib plus rituximab for CLL
Checkpoint inhibitor/bispecific antibody combo: REGN2810 and REGN1979 in B-lymphoid malignancies
MUK Nine b: OPTIMUM, paving the way to effectively treat newly diagnosed high-risk MM
Results of the Phase III DASISION trial and the future of CML treatment
Why should elderly AML patients take part in clinical trials?